The secondary outcomes were non-inferiority ( within 10 % levels ) at age 18 weeks for the proportion of participants in the 2 +1 group compared with the 3 +0 group with serotypes 1 , 5 , and 14 specific IgG of at least 02 g/mL ; the proportion of participants with PCV10 serotype-specific IgG of at least 02 g/mL and opsonophagocytic activity reciprocal titre of at least 8 at ages 18 weeks and 10 months ; and nasopharyngeal pneumococcal serotype-specific carriage rates at age 9 months in each study group .